1/20/11 – F.D.A. Sees Promise in Alzheimer’s Imaging Drug

An advisory committee to the Food and Drug Administration recommended unanimously Thursday that the agency approve the first test — a brain scan — that can show the characteristic plaques of Alzheimer’s disease in the brain of a living person.

Read the full article at The New York Times